The DOI matches its Crossref record; 217 of the 217 references it cites were found in a registry or an index.
Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009
Open accessAbstract
Insulin resistance is a hallmark of type 2 diabetes mellitus and is associated with a metabolic and cardiovascular cluster of disorders (dyslipidaemia, hypertension, obesity [especially visceral], glucose intolerance, endothelial dysfunction), each of which is an independent risk factor for cardiovascular disease (CVD). Multiple prospective studies have documented an association between insulin resistance and accelerated CVD in patients with type 2 diabetes, as well as in non-diabetic individuals. The molecular causes of insulin resistance, i.e. impaired insulin signalling through the phosphoinositol-3 kinase pathway with intact signalling through the mitogen-activated protein kinase pathway, are responsible for the impairment in insulin-stimulated glucose metabolism and contribute to the accelerated rate of CVD in type 2 diabetes patients. The current epidemic of diabetes is being driven by the obesity epidemic, which represents a state of tissue fat overload. Accumulation of toxic lipid metabolites (fatty acyl CoA, diacylglycerol, ceramide) in muscle, liver, adipocytes, beta cells and arterial tissues contributes to insulin resistance, beta cell dysfunction and accelerated atherosclerosis, respectively, in type 2 diabetes. Treatment with thiazolidinediones mobilises fat out of tissues, leading to enhanced insulin sensitivity, improved beta cell function and decreased atherogenesis. Insulin resistance and lipotoxicity represent the missing links (beyond the classical cardiovascular risk factors) that help explain the accelerated rate of CVD in type 2 diabetic patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–217 of 217
Insulin-sensitive tyrosine kinase: relationship with in vivo insulin action in humans
Nyomba, B. L. G., Ossowski, V., Bogardus, C., & Mott, D. M. (1990) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1990.258.6.e964 · Cited by 55
Nakao, J., Ito, H., Kanayasu, T., & Murota, S. (1985) · Diabetes · doi:10.2337/diab.34.2.185 · Cited by 54
Lincoff, A. M., Wolski, K., Nicholls, S. J., & Nissen, S. E. (2007) · JAMA · doi:10.1001/jama.298.10.1180 · Cited by 52
Chen, Y. I., Jeng, C. Y., Hollenbeck, C. B., Wu, M. ‐., & Reaven, G. M. (1988) · Journal of Clinical Investigation · doi:10.1172/jci113572 · Cited by 51
Koopmans, S. J., Kushwaha, R. S., & DeFronzo, R. A. (1999) · Metabolism · doi:10.1016/s0026-0495(99)90081-1 · Cited by 48
Self-citationKudolo, G. B., Bressler, P., & DeFronzo, R. A. (1997) · Journal of Lipid Mediators and Cell Signalling · doi:10.1016/s0929-7855(97)00023-0 · Cited by 48
Self-citationRosiglitazone treatment increases nitric oxide production in human peripheral skin
Vinik, A. I., Stansberry, K. B., & Barlow, P. M. (2003) · Journal of Diabetes and its Complications · doi:10.1016/s1056-8727(03)00006-0 · Cited by 46
Is insulin resistance atherogenic? Possible mechanisms
DeFronzo, R. A. (2006) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2006.05.002 · Cited by 46
Self-citationRana, J. S., Visser, M. E., Arsenault, B. J., Després, J., Stroes, E. S. G., Kastelein, J. J. P., Wareham, N. J., Boekholdt, S. M., & Khaw, K. (2009) · International Journal of Cardiology · doi:10.1016/j.ijcard.2009.03.123 · Cited by 45
Dietary trans fatty acids and composition of human atheromatous plaques
Stachowska, E., Dołęgowska, B., Chlubek, D., Wesołowska, T., Ciechanowski, K., Gutowski, P., Szumiłowicz, H., & Turowski, R. (2004) · European Journal of Nutrition · doi:10.1007/s00394-004-0479-x · Cited by 40
Stout, R. W. (1971) · Diabetologia · doi:10.1007/bf01219472 · Cited by 31
Obesity and insulin resistance in man. A dose response study
Bonadonna, R. C., Groop, L., Kraemer, N., Ferrannini, E., Prato, S. D., & DeFronzo, R. A. (1990) · Cited by 30
Self-citationExenatide: first-in-class incretin mimetic for the treatment of Type 2 diabetes mellitus
Triplitt, C. L., & DeFronzo, R. A. (2006) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.1.3.329 · Cited by 27
Self-citationInsulin sensitivity in familial hypercholesterolemia
Galvan, A. Q., Santoro, D., Natali, A., Sampietro, T., Boni, C. D., Masoni, A., Buzzigoli, G., & Ferrannini, E. (1993) · Metabolism · doi:10.1016/0026-0495(93)90138-e · Cited by 26
Targeting Insulin Resistance and β-Cell Dysfunction: The Role of Thiazolidinediones
Prato, S. D., & Marchetti, P. (2004) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2004.6.719 · Cited by 19
Miyazaki, Y., De Filippis, E., Bajaj, M., Wajcberg, E., Glass, L., Triplitt, C., Cersosimo, E., Mandarino, L. J., & Defronzo, R. A. (2005) · The British Journal of Diabetes & Vascular Disease · doi:10.1177/14746514050050010601 · Cited by 18 · cited 1×
“Thiazolidinediones also inhibit release of proinflammatory, prothrombotic, atherogenic adipocytokines from fat tissue [139, 141, 172, 203] and redistribute fat from visceral (atherosclerotic equivalent) to subcutaneous depots [189, 190].”
BackgroundSelf-citationInsulin resistance, hypertension and cellular ion transport systems
Solini, A., & DeFronzo, R. A. (1992) · Acta Diabetologica · doi:10.1007/bf00573488 · Cited by 6
Self-citation
Cited by
DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.19 · Cited by 2,611
Self-citationHomeostasis, Inflammation, and Disease Susceptibility
Kotas, M. E., & Medzhitov, R. (2015) · Cell · doi:10.1016/j.cell.2015.02.010 · Cited by 1,213
Insulin Resistance, Hyperglycemia, and Atherosclerosis
Bornfeldt, K. E., & Tabas, I. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.07.015 · Cited by 995
Insulin resistance and hyperglycaemia in cardiovascular disease development
Laakso, M., & Kuusisto, J. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.29 · Cited by 858
Yuan, T., Yang, T., Chen, H., Fu, D., Hu, Y., Wang, J., Yuan, Q., Yu, H., Xu, W., & Xie, X. (2019) · Redox Biology · doi:10.1016/j.redox.2018.09.025 · Cited by 743
Metadata
- Authors
- DeFronzo, R. A.
- Venue
- Diabetologia
- Published
- 2010-04-02
- Volume
- 53
- Issue
- 7
- Pages
- 1270-1287
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2162078466
- Cited by
- 879
- References
- 217
- FWCI
- 36.33
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.